Ferric derisomaltose
- Generic Name
- Ferric derisomaltose
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H34FeO16
- CAS Number
- 1345510-43-1
- Unique Ingredient Identifier
- AHU547PI9H
- Background
Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non life-threatening, iron deficiency may considerably...
- Indication
This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron preparations or insufficient clinical response to orally administered iron. Ferric derisomaltase is also indicated for patients with non-hemodialysis dependent chronic kidney disease. In Australia and United Kingdom, ferric deris...
- Associated Conditions
- Iron Deficiency Anemia (IDA), Requirement for rapid iron delivery
- Associated Therapies
- -
Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- University of Glasgow
- Target Recruit Count
- 1160
- Registration Number
- NCT02642562
- Locations
- 🇬🇧
New Cross Hospital, Wolverhampton, United Kingdom
🇬🇧St. George's Hospital, Tooting, United Kingdom
🇬🇧Torbay Hospital, Torquay, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.